New drug NHL907 tested for safety in healthy people
NCT ID NCT07580924
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing the safety and tolerability of a new drug called NHL907 in 64 healthy adults aged 18 to 60. Participants receive multiple oral doses of NHL907 or a placebo. The study measures side effects and how the drug moves through the body, but does not aim to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NHL907
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY ADULT PARTICIPANTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CMAX Clinical Research Pty Ltd
RECRUITINGAdelaide, South Australia, 5000, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill ACC017 be safely dosed? a trial seeks answers
- Can a fingerprint scan replace traditional drug tests?
- Gut feeling: could probiotics soothe the mind?
- A window to the brain? eye signals may track dopamine
- Can a common heartburn pill change how a cancer drug works?
- Breathing exercises may rewire tongue control — a pilot study puts the idea to the test